Literature DB >> 14595154

Chronic lithium nephropathy: MR imaging for diagnosis.

Maria Teresa Farres1, Pierre Ronco, David Saadoun, Philippe Remy, François Vincent, Antoine Khalil, Alain Ferdinand Le Blanche.   

Abstract

PURPOSE: To evaluate the appearance of lithium nephropathy at magnetic resonance (MR) imaging.
MATERIALS AND METHODS: Sixteen patients with renal insufficiency and clinical and laboratory evidence of nephropathy secondary to therapy with lithium salts were examined with a 1.5-T MR imaging unit with T1-weighted, T2-weighted fast imaging with steady-state precession (true FISP), rapid acquisition with relaxation enhancement, half-Fourier turbo spin-echo, and gadolinium-enhanced (FISP three-dimensional MR angiographic) sequences. Renal size and the presence, number, location and size of parenchymal cysts were analyzed. The cysts in each kidney were defined as rare (fewer than 10 cysts), sparse (between 10 and 30 cysts), abundant (30-60 cysts), or very abundant (more than 60 cysts).
RESULTS: The mean length of both kidneys was 104 mm +/- 9 in seven cases, and one or both kidneys were less than 90 mm in length in nine cases. Renal microcysts measuring from 1 to 2 mm were detected in all patients. They were either very abundant (n = 12), abundant (n = 2), or sparse (n = 2). The cysts were located with equal abundance in both the cortex and the medulla in 11 cases and were predominantly located in the renal cortex in five cases. No renal artery stenosis was present.
CONCLUSION: Microcysts secondary to long-term lithium therapy can be detected with MR imaging. Copyright RSNA, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595154     DOI: 10.1148/radiol.2292020758

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  MRI findings in chronic lithium nephropathy: a case report.

Authors:  Aubrey Slaughter; Tarun Pandey; Kedar Jambhekar
Journal:  J Radiol Case Rep       Date:  2010-08-01

2.  Long-Term Lithium Use and Risk of Renal and Upper Urinary Tract Cancers.

Authors:  Anton Pottegård; Jesper Hallas; Boye L Jensen; Kirsten Madsen; Søren Friis
Journal:  J Am Soc Nephrol       Date:  2015-05-04       Impact factor: 10.121

3.  Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells.

Authors:  Yang Gao; Melissa J Romero-Aleshire; Qi Cai; Theodore J Price; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-24

Review 4.  Lithium in the Kidney: Friend and Foe?

Authors:  Mohammad Alsady; Ruben Baumgarten; Peter M T Deen; Theun de Groot
Journal:  J Am Soc Nephrol       Date:  2015-11-17       Impact factor: 10.121

5.  Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus.

Authors:  Theun de Groot; Anne P Sinke; Marleen L A Kortenoeven; Mohammad Alsady; Ruben Baumgarten; Olivier Devuyst; Johannes Loffing; Jack F Wetzels; Peter M T Deen
Journal:  J Am Soc Nephrol       Date:  2015-11-16       Impact factor: 10.121

Review 6.  [Interstitial nephritis].

Authors:  J Halbritter; C Mayer; F M Rasche; K Amann; T H Lindner
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

Review 7.  Lithium nephrotoxicity revisited.

Authors:  Jean-Pierre Grünfeld; Bernard C Rossier
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

8.  Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease.

Authors:  Shixin Tao; Vijayakumar R Kakade; James R Woodgett; Pankaj Pandey; Erin D Suderman; Madhumitha Rajagopal; Reena Rao
Journal:  Kidney Int       Date:  2015-01-28       Impact factor: 10.612

9.  Cystic kidney disease in a patient with long-term lithium therapy.

Authors:  An Vanacker; Jo Van Dorpe; Bart Maes
Journal:  NDT Plus       Date:  2009-01-26

10.  Solid renal tumours of collecting duct origin in patients on chronic lithium therapy.

Authors:  Maarten B Rookmaaker; Heleen A J M van Gerven; Roel Goldschmeding; Walther H Boer
Journal:  Clin Kidney J       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.